MedTrace Logo

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

NCT05393245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19467

Last updated 2024-12-04

Study results available
· View outcomes & findings →

Summary

The aim of this real world study is to assess the safety profile of tiotropium/olodaterol (Tio/Olo).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium+Olodaterol

Tiotropium+Olodaterol

DEVICE

Spiolto Respimat

Spiolto Respimat Inhaler device

DRUG

Long-acting muscarinic antagonists (LAMAs)

Long-acting muscarinic antagonists (LAMAs)

DRUG

Long-acting β2-agonists (LABAs)

Long-acting β2-agonists (LABAs)

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2022-12-07
Completion
2022-12-07

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393245 on ClinicalTrials.gov